IDWeek 2026: olorofim shows promise in second-line invasive aspergillosis

Overall, the findings of the trial are promising, particularly in relation to renal safety. Given the urgent need for an orally administered, safer alternative to AmB, olorofim has strong potential to receive FDA approval for IA in 2027.

GlobalData Healthcare October 26, 2026

Mould-active azole antifungals (MAAs) remain the SOC for the treatment of IA. Credit: Fahroni via Shutterstock.com.

Unlock FREE Access to Premium Content

Discover exclusive forecasts, analyst insights, and in-depth clinical trials industry analysis across drug development, clinical research, and trial innovation.

With a free Clinical Trials Arena profile, you can:

Access exclusive analyst commentary and expert insights
View premium forecasts and data-driven clinical trial intelligence
Stay up to date with clinical trial news, regulatory updates, and industry trends
Receive alerts when new premium content is published